A common and unsightly skin cancer that can turn deadly has been undetectable for more than a year in a patient treated with ...

New global analysis calls for urgent, targeted interventions as aging populations face rising rates of skin cancer.

Michael E. Kasper, MD, FACRO, discussed unmet needs in skin cancer treatment and addressed misconceptions among patients and ...

The U.S. Food and Drug Administration has approved the humanized monoclonal antibody Zynyz (retifanlimab-dlwr) as the first ...

Patients with CSCC who had lymphovascular invasion had a greater incidence of metastasis and disease-specific death than those without.

"Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial" was originally created and published by ...

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or ...

The FDA has approved Zynyz as a first-line treatment in combination with chemo and as a single-agent following progression in ...